---
title: "Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286678206.md"
description: "U.S. cancer centers are rapidly enrolling patients in an expanded access program for Revolution Medicines' pancreatic cancer drug, daraxonrasib, after positive trial results showed significant survival rate improvements. Despite this, Revolution Medicines' stock (NASDAQ: RVMD) has declined, linked to the FDA's approval of the access program. The Phase 3 RASolute 302 trial indicated a median overall survival of 13.2 months with daraxonrasib, compared to 6.7 months with standard chemotherapy."
datetime: "2026-05-17T16:27:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286678206.md)
  - [en](https://longbridge.com/en/news/286678206.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286678206.md)
---

# Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report

U.S. cancer centers are swiftly enrolling patients in an expanded access program for a pancreatic cancer drug developed by Revolution Medicines Inc. (NASDAQ: RVMD) following positive clinical trial results that revealed a significant extension in survival rates for those with advanced disease. Revolution Medicines' stock price has experienced a decline recently. The drop in RVMD stock is attributed to the FDA's approval of the company's expanded access program for their experimental pancreatic cancer drug, daraxonrasib. In April, Revolution Medicines released encouraging topline outcomes from the Phase 3 RASolute 302 trial of daraxonrasib for metastatic pancreatic cancer. During the trial, daraxonrasib showcased noteworthy enhancements in progression-free survival and overall survival, pivotal factors in cancer treatments. Daraxonrasib displayed a median overall survival of 13.2 months, a stark comparison to the 6.7 months seen with standard chemotherapy.

### Related Stocks

- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [US Cancer Clinics Rush to Access Revolutionary Pancreatic Cancer Drug Daraxonrasib](https://longbridge.com/en/news/286405546.md)
- [Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report](https://longbridge.com/en/news/286590889.md)
- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)
- [BeOne Wins First-in-Class U.S. FDA Nod for BCL2 Drug in Relapsed Mantle Cell Lymphoma](https://longbridge.com/en/news/286330888.md)
- [US FDA authorizes early access to Revolution's pancreatic cancer pill](https://longbridge.com/en/news/284922598.md)